CAJ | 학술논문

目的：观察奥沙利铂联合多西他赛治疗卵巢癌的疗效及其对患者肿瘤标志物、血管内皮生长因子（ EG-FR）表达的影响。方法分别收集卵巢癌病例80例，良性卵巢肿瘤病例及健康志愿者各40例，比较各组间血清肿瘤标志物CA199、CEA、CA125、CA153和EGFR水平；80例卵巢癌患者随机分为2组，对照组（多西他赛＋卡铂）和观察组（多西他赛＋奥沙利铂）各40例，比较2组间疗效差异及血清肿瘤标志物、EGFR水平差异。结果卵巢癌患者血清肿瘤标志物CA199、CEA、CA125、CA153和EGFR水平显著高于健康对照组和良性卵巢肿瘤组，P＜0．05。不同治疗结局卵巢癌患者血清肿瘤标志物及血管内皮生长因子水平存在显著差异（P＜0．05），疗效越佳者血清肿瘤标志物及血管内皮生长因子水平越低。完成3个疗程的化疗后，观察组总有效率为60．00％，显著高于对照组的37．50％，观察组血清肿瘤标志物及血管内皮生长因子水平显著低于对照组，P＜0．05。结论奥沙利铂联合多西他赛能有效抑制卵巢癌患者肿瘤标志物及血管内皮生长因子表达，可作为晚期卵巢癌治疗方案的一种较优选择。
목적：관찰오사리박연합다서타새치료란소암적료효급기대환자종류표지물、혈관내피생장인자（ EG-FR）표체적영향。방법분별수집란소암병례80례，량성란소종류병례급건강지원자각40례，비교각조간혈청종류표지물CA199、CEA、CA125、CA153화EGFR수평；80례란소암환자수궤분위2조，대조조（다서타새＋잡박）화관찰조（다서타새＋오사리박）각40례，비교2조간료효차이급혈청종류표지물、EGFR수평차이。결과란소암환자혈청종류표지물CA199、CEA、CA125、CA153화EGFR수평현저고우건강대조조화량성란소종류조，P＜0．05。불동치료결국란소암환자혈청종류표지물급혈관내피생장인자수평존재현저차이（P＜0．05），료효월가자혈청종류표지물급혈관내피생장인자수평월저。완성3개료정적화료후，관찰조총유효솔위60．00％，현저고우대조조적37．50％，관찰조혈청종류표지물급혈관내피생장인자수평현저저우대조조，P＜0．05。결론오사리박연합다서타새능유효억제란소암환자종류표지물급혈관내피생장인자표체，가작위만기란소암치료방안적일충교우선택。
Objective To analyze the effect of oxaliplatin combined with docetaxel for patients with ovarian cancer ,and its influence on the tumor markers and vascular endothelial growth factor ( VEGF) .Methods 80 cases of ovarian cancer ,and 40 cases of benign ovarian tumor patients and healthy volunteers were separately collected , then the difference of serum levels of tumor markers such as CA199,CEA,CA125,CA153 and EGFR of the 3 groups were be compared.80 cases of patients with ovari-an cancer were randomly divided into 2 groups,the control group (docetaxel+carboplatin)and the observation group (oxaliplatin+docetaxel),each group had 40 cases,Then the difference of curative effect and serum levels of tumor markers and EGFR of the 2 groups were compared .Results The serum levels of tumor markers such as CA 199,CEA,CA125,CA153 and EGFR of patients with ovarian cancer were all higher than benign ovarian tumor patients and healthy volunteers ,P<0.05.There were significant differences in serum levels of tumor markers and EGFR in ovarian cancer patients with different treatment outcomes (P<0.05), the better the efficacy ,the lower the level of serum tumor markers and VEGF .After third chemotherapy treatment ,,the total effi-ciency of the observation group was 60%which was significantly higher than that that of the control group 37.50%,and the serum levels of tumor markers and EGFR of the observation group were all lower than those of the control group ,P<0.05.Conclusion Oxaliplatin combined with docetaxel can effectively inhibit the expression of tumor markers and EGFR for patients with ovarian cancer,which can be used as a good choice for advanced ovarian cancer .